I-Bridge Capital

I-Bridge Capital is a venture capital firm focused on healthcare and life science investments. It has made two investments, including a Series A investment in...

I-Bridge Capital

I-Bridge Capital is a venture capital firm focused on healthcare and life science investments. It has made two investments, including a Series A investment in CMAB Biopharma on January 2, 2018. The firm has two portfolio exits, with CMAB Biopharma being its most recent exit on March 17, 2021.

Website

ibridgecapital.org

linkedin.com/company/i-bridge-capital

General information

Firm type

Private Equity

Year founded

—

AUM

Undisclosed

Location

Region

Asia

Country

Hong Kong

City

Hong Kong

Corporate office

Hong Kong, Hong Kong

What types of investments does I-Bridge Capital typically make?

I-Bridge Capital focuses on early-stage investments, specifically targeting startup and seed-stage companies (per public record). The firm does not disclose a specific sector focus, but its Hong Kong base suggests a regional emphasis on Asia.

In which geographic region does I-Bridge Capital operate?

The firm is headquartered in Hong Kong and likely concentrates its investments in Asia, based on its location (per public record). No additional offices or cross-regional operations have been disclosed.

Is I-Bridge Capital a single family office or a traditional private equity firm?

I-Bridge Capital is classified as an asset manager with a private equity subtype (per Altss research). It does not publicly identify as a family office. The lack of disclosed principals or wealth origin leaves its ownership structure unclear.

Does I-Bridge Capital participate in fund commitments or only direct deals?

The firm's investment approach is not detailed in public sources. As an early-stage private equity manager, it may make direct equity investments, but no information on fund-of-funds participation or co-investments is available.

How does I-Bridge Capital source its deal flow?

The firm's sourcing methodology is not publicly documented. Given its Hong Kong base, it likely relies on local networks, but no proprietary deal channels have been identified.

Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: Jun 3, 2026. Continuous refresh with full update cycles at least every 30 days.